Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis
Table 2
Median sum of volumes of target angiomyolipoma lesions at baseline, EOT, and week 48 of non-interventional follow-up phase, and percentage change from baseline to EOT/week 48 of non-interventional follow-up phase and from EOT to week 48 of non-interventional follow-up phase.